1
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Differentiation of the Fetal Gonad

      Hormone Research in Paediatrics

      S. Karger AG

      Testis, Anti-Müllerian hormone, Gonadotrophins, Inhibins, Ovary, Steroidogenesis

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Gonadal differentiation may be divided into four stages: pregonadal, indifferent, primary sex differentiation, and secondary sex differentiation. Sertoli cells appear at 6-7 weeks and Ley dig cells differentiate at 8 weeks, but in ovaries, primary sex differentiation occurs much later. Testosterone secretion peaks at 12-16 weeks causing male secondary sex development together with the appearance of anti-Müllerian hormone. Fetal testis is able to synthesize and secrete inhibins. Lower circulating luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in male than in female fetuses at midgestation suggest that the fetal pituitary is already responsive to the gonadal hormones. Placental human chorionic gonadotrophin may regulate testosterone synthesis at midgestation, and both LH and FSH are likely to have some regulatory effect on fetal gonads during the last third of gestation.

          Related collections

          Author and article information

          Journal
          HRE
          Horm Res Paediatr
          10.1159/issn.1663-2818
          Hormone Research in Paediatrics
          S. Karger AG
          978-3-8055-5740-5
          978-3-318-01971-1
          1663-2818
          1663-2826
          1992
          1992
          03 December 2008
          : 38
          : Suppl 2
          : 66-71
          Affiliations
          Departments of Pediatrics and Pathology, University of Helsinki, Finland
          Article
          182601 Horm Res 1992;38:66–71
          10.1159/000182601
          1292985
          © 1992 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Categories
          Intersexuality

          Comments

          Comment on this article